Imiglucerase
Mechanism :
Imiglucerase is an analogue of the human enzyme, (beta)-glucocerebrosidase produced by recombinant DNA technology. (beta)-Glucocerebrosidase is a lysosomal glycoprotein enzyme which catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide.
Indication :
Contraindications :
There are no known contraindications to the use of imiglucerase.
Dosing :
<2 years:
Safety and efficacy not established.
>2 years:
2.5 units/kg given intravenously over 1-2 hours thrice a week or 30-60 units/kg given intravenously every 2 weeks.
Adverse Effect :
Hypersensitivity reactions have been reported, manifested by flushing, pruritus, urticaria, chest discomfort, angioedema, cyanosis, respiratory symptoms, and hypotension. Additional adverse reactions that have been reported include: fatigue, abdominal pain, diarrhea, nausea, backache, rash, headache, dizziness, fever with chills, and tachycardia.
Interaction :
No known drug interactions.
Hepatic Dose :
No dose adjustments are recommended.